Explore the frontier of life sciences and healthcare innovation. From breakthrough therapeutics and longevity research to the deep tech investments shaping tomorrow's treatments, discover the trends and breakthroughs redefining global health.
Culture Biosciences closed its Series C to scale the Stratyx 250 and Console AI platform. The digital biomanufacturing market is projected at $22.16B by 2034. Three models are competing to define the infrastructure standard.
A field comparison of five AI drug discovery platforms — Isomorphic Labs, Recursion, Insitro, Insilico Medicine, and Schrödinger — their approaches, data, and odds of surviving to approval.
Life Biosciences dosed the first patient with partial epigenetic reprogramming in June 2026. NewLimit raised $435M for liver-cell trials in 2027. The era of cellular rejuvenation has begun.
MindRank AI closed a $52M Series B to advance MDR-001, an AI-designed oral GLP-1 receptor agonist now in Phase III obesity trials in China. The round validates AI-native drug discovery at late-stage clinical development.
Crystalys Therapeutics closed an oversubscribed $130M Series B to push dotinurad, a next-generation URAT1 inhibitor, through Phase 3 trials for gout. The drug is already approved in four Asian markets.
Pentagon has directed $965.2M toward autonomous biofoundries for defence medical countermeasures. BioFabUSA demonstrates world's first AI-enabled SMAC platform at FDA. FY27 NDAA authorizes forward-deployable biomanufacturing pilot. BioMADE, T-BRSC, DBIMP form three-layer infrastructure.
The U.S. Army's DEVCOM CBC is developing deployable bioprinting stations that could print skin grafts on the frontline — a technology bridging battlefield trauma care and regenerative biomanufacturing.
AI-native antibody design platforms are approaching clinical validation in 2026. BigHat Biosciences leads with $105M raised, AbbVie and Eli Lilly partnerships, and a GI cancer ADC nearing trials.
Get daily updates on the technologies and investment opportunities shaping the next decade — from AI infrastructure and autonomous systems to biotech, space, and defence. Curated analysis, no noise.
